ClinicalTrials.govrestricted
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
ClinicalTrials.gov study NCT01692899. IPD Sharing: Not stated. Countries: 0. Publications: 1.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8